Reshma Kewalramani - 17 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2026
Net transactions value
-$3,170,498
Form type
4
Filing time
19 Feb 2026, 16:16:37 UTC
Previous filing
18 Feb 2026
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kewalramani Reshma CEO & President, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 19 Feb 2026 0001735944

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +16,326 +12% $0.000000 149,813 17 Feb 2026 Direct F1
transaction VRTX Common Stock Tax liability $3,170,498 -6,554 -4.4% $483.75 143,259 17 Feb 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests in installments beginning on February 20, 2027.